NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

The influential National Comprehensive Cancer Network (NCCN, www.nccn.org) has given Provenge its top rating. Although Medicare often follows NCCN guidelines, “In this climate I’m not sure that [NCCN] ...

Medicare said this week it will pay for two cancer treatments with hefty price tags -- and lingering questions: Avastin, the controversial drug shot down by an Food and Drug Administration panel on ...

November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

Dendreon Corp. said its experimental drug Provenge reduced the risk of death 20 percent in a study of men with advanced prostate cancer, sending the company's stock up the most in more than a year.

announced today that four abstracts featuring PROVENGE^® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data ...

Seattle-based cancer drug developer Dendreon Corp. plans to start hiring hundreds of workers later this year for a plant being built in Seal Beach, according to its chief financial officer. Dendreon ...